Top Stem Cells Stocks
There hasn't been much debate in the press recently about stem cells, however, there has been plenty of news. For example, a mini-kidney was grown from stem cells by scientists. Researchers have now found a way to grow aged brain cells from stem cells. And finally, Plantar Fasciitis is now being treated with stem cells.
Extensive stem cell research is being done relating to the treatment of cancer, Parkinson's disease, and multiple sclerosis. Due to all the controversy about embryonic stem cells, alternative sources are being studied, such a teeth and umbilical cord blood.
Several companies are involved in some aspect of stem cells and stem cell research. WallStreetNewsNetwork.com has turned up over a dozen stem cell stocks, and over half a dozen of which are generating profits.
Alexion Pharmaceuticals (NASDAQ: ALXN) is a Connecticut based company with a $24.6 billion market cap that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a price to earnings ratio of 71 and a forward PE of 37. Earnings for the latest quarter were up 1.7%% on a 36.1% boost in revenues.
Integra Lifesciences Holdings (NASDAQ: IART) is a New Jersey based company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The company recently generated a 59 cent loss per share on a 1.5% increase in sales. It has a market cap of $1.34 billion.
Cellgene (NASDAQ: CELG) is a $69.6 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. They have a patent on placental stem cell recovery. The stock sports a PE ratio of 49 and a forward PE of 23. Quarterly earnings were down 12.2%% on an 18%% revenue increase.
Disclosure: Author did not own any of the above at the time the article was written.
The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.